AlzeCure Pharma: Positive FDA feedback regarding ACD440 in orphan disease - Redeye

Redeye comments on yesterday’s news that AlzeCure has received positive feedback from the FDA regarding the clinical path for ACD440 in the rare pain disorder erythromelalgia.

Länk till analysen i sin helhet: https://www.redeye.se/research/1115394/alzecure-pharma-positive-fda-feedback-regarding-acd440-in-orphan-disease?utm_source=finwire&utm_medium=RSS